Diagnostic and prognostic value of the peripheral natural killer cell levels in gastric cancer

YU-YAN CHEN1,2*, YING FENG1*, QIN-SHENG MAO1, PENG MA1, JIA-ZHOU LIU1,2, WEI LU1, YI-FEI LIU4, XI CHEN1, YI-LIN HU1,2 and WAN-JIANG XUE1,2

1Department of Gastrointestinal Surgery, Affiliated Hospital of Nantong University; 2Research Center of Clinical Medicine, Nantong University, Affiliated Hospital of Nantong University; Departments of 3Hematology and 4Pathology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China

Received January 30, 2020; Accepted June 24, 2020

DOI: 10.3892/etm.2020.9101

Abstract. Peripheral blood lymphocyte subsets have been reported to be useful as prognostic and/or diagnostic markers for patients with cancer. However, the clinical value of peripheral blood lymphocyte subsets in gastric cancer (GC) has remained elusive. In the present study, peripheral CD3+, CD4+ and CD8+ T lymphocytes, B cells (CD19+), regulatory T cells (Tregs; CD4+CD25+CD127+) and natural killer (NK) cells (CD3+CD16+CD56+) were detected by flow cytometry in 122 patients with GC, 80 healthy donors (HDs) and 80 patients with gastric ulcer (GU). NK cells (CD56+) were detected by immunohistochemical (IHC) analysis in 20 GC and three GU tissue samples. A receiver-operating characteristic (ROC) curve was used to determine the threshold of the peripheral NK cell level and survival analysis was performed to assess its prognostic value in patients with GC. The results indicated that the peripheral NK cell proportion in patients with GC (18.77%) was significantly higher than that in the HD (12.19%) and GU (12.74%) groups. IHC analysis suggested that the NK level in GC tumor samples was correlated with that in paired serum samples. ROC curve analysis indicated that the peripheral NK cell level (15.16%) was able to effectively identify patients with GC, a diagnostic sensitivity of 75.41% and a specificity of 77.45% were determined. Multivariate logistic regression analysis revealed that the peripheral NK cell level was independently associated with the T stage and survival analysis demonstrated that high levels of peripheral NK cells were associated with poor prognosis of patients with GC. In conclusion, the peripheral NK cell level may be a diagnostic and prognostic marker for patients with GC.

Introduction

Gastric cancer (GC) is the fourth leading cause of cancer-associated mortality among the most common malignancies, with nearly 760,000 deaths resulting from GC each year (1,2). GC has no specific manifestation at the early stage and >80% of patients with GC present with advanced or late-stage GC upon diagnosis (3). Thus, early diagnosis of GC is particularly important and more effective non-invasive diagnostic markers for early GC are urgently required.

Peripheral lymphocyte subsets are important cells in the immune system (4,5). Peripheral blood lymphocyte subsets mainly include T lymphocytes, B lymphocytes (CD19+) and natural killer (NK) cells (CD3+CD16+CD56+). According to the presence of different cell surface markers, T lymphocytes may be divided into various phenotypic and functional groups, including CD3+, CD4+ and CD8+ T cells, and regulatory T cells (Tregs; CD4+CD25+CD127+). T cells and NK cells are mainly involved in cellular immunity, while B cells are involved in humoral immunity (5-8).

Changes in the peripheral lymphocyte subsets of tumor patients not only reflect the state of immune functions but are also closely linked to the clinical phenotype of tumors (9). Low levels of CD3+ T cells in peripheral blood are associated with the poor prognosis of patients with colon, endometrial or lung cancer (10-12), while low levels of CD4+ and CD8+ T cells are associated with the poor prognosis of patients with breast (13), colorectal (14) and cervical cancer (15). Certain studies have indicated that the proportion of CD4+ and CD8+ T cells tends to be stable, fluctuating between 1.3 and 2.0% in healthy individuals and may also be a good prognostic marker for lung and cervical cancer (16,17). CD19 is able to specifically reflect changes in B lymphocytes and CD19+ B cells were proven to be a prognostic marker for nasopharyngeal carcinoma (18). Tregs are a group of lymphocytes that negatively regulate the immune response and have an important role in maintaining self-tolerance and avoiding excessive immune damage to the body. Studies have suggested that high levels of Tregs lead
to poor prognosis in patients with colorectal or esophageal cancer (19,20). NK cells are a group of lymphocytes with innate immune function. Low levels of NK cells have been indicated to be associated with a favorable prognosis in patients with esophageal or pancreatic cancer (21,22). In spite of the increase of clinical research on lymphocyte subsets in peripheral blood, only a few systematic studies have reported on the distribution of lymphocyte subsets in the peripheral blood of patients with GC (23).

In the present study, the distribution of peripheral lymphocyte subsets in healthy donors (HDs), patients with gastric ulcer (GU) and patients with GC was explored and the value of NK cells as a diagnostic and prognostic marker for GC was revealed.

Materials and methods

Patients. To determine the minimum sample size in the HD, GU and GC groups for inclusion in the present study, the following formula was used to calculate the sample capacity: $n_{1}=Z_{1}^{2} \cdot \text{Sen}(1-\text{Sen})/\Delta^{2}$, $n_{2}=Z_{2}^{2} \cdot \text{Spe}(1-\text{Spe})/\Delta^{2}$, where $n_{1}$ is the case sample capacity, $n_{2}$ the control sample capacity, Sen is the sensitivity, Spe is the specificity, $Z_{1}=Z_{2}=95\%$ CI = 1.96 and $\Delta=0.1$. The minimum sample capacity was determined to be 72 for GC and 68 for GU and HD. Peripheral blood samples were collected from 122 patients with GC prior to radical D2 surgery for GC at the Affiliated Hospital of Nantong University (Nantong, China) from January 2013 to December 2013. Informed consent was obtained from all included participants. A total of 122 patients with primary GC scheduled for radical D2 surgery for GC were selected according to the following criteria: i) Patients were not older than 80 years; ii) patients did not receive any chemotherapy drugs prior to or after surgery; iii) patients had no known infectious diseases within 1 month prior to surgery; iv) patients had no obvious symptoms of fever; v) no blood transfusion was performed during surgery and within 1 month after surgery or 3 months prior to surgery; vi) no infection or other complications occurred after surgery; and vii) tumors were TNM stage I, II or III. A uniform follow-up schedule of clinical surveys was performed based on the guidelines of the Japanese GC Association Classification of Gastric Carcinoma, 13th edition (24). The present study was approved by the Ethics Committee of the Affiliated Hospital of Nantong University (Nantong, China) in accordance with the tenets of the Declaration of Helsinki.

Blood sample collection and flow cytometry. Fasting venous blood samples were collected in heparin anticoagulant tubes and the samples were incubated with four-color monoclonal antibodies at room temperature for 15 min as follows: A CD3-FITC/CD8-PE/CD45-peridinin chlorophyllI (PerCP)/CD4-allophycocyanin (APC) four-color kit (Mindray Medical International Co., Ltd.; cat. no. 340443; 1:1) and a CD3-FITC/CD16+56-phycocerythrin (PE)/CD45-PerCP/CD19-APC four-color kit (Mindray Medical International Co., Ltd.; cat. no. 652834; 1:1) were used to identify CD3+, CD4+, CD8+ and CD19+ T cells and NK cells, respectively, while a CD45-PerCP/CD4-APC/CD25-PE/CD127-FITC four-color kit (BD Biosciences; cat. no. 6029623, 1:1) was used to identify Tregs. After 15 min, flow cytolytic lysing agent (Mindray Medical International Co., Ltd.; cat. no. 2018110601) was added. The aforementioned kits were used according to the manufacturers' protocols and all of the prepared samples were assayed using a BriCyte E6 flow cytometer (Mindray) and a minimum of 3x10^4 cells were recorded. A particular uniform protocol was followed that was published previously (9).

Immunohistochemical (IHC) analysis. In brief, GC or GU tissues were paraffin-embedded and cut into sections (4 µm thick). The sections were dewaxed in xylene and then rehydrated using a graded ethanol series. After three washes with PBS, the sections were incubated overnight at 4°C with the anti-CD56 antibody (Fuzhou Maixin Biotech Co., Ltd.; cat. no. Kit-0028, 1:100), an NK cell marker. After three washes with PBS, the sections were incubated with a horseradish peroxidase-conjugated secondary antibody (Dako, Agilent Technologies, Inc.; cat. no. S0809; 1:150) for 2 h at room temperature. Finally, hematoxylin and xylene were used to counterstain the sections. The staining intensity was scored manually in the microscope by two independent experienced pathologists. Brown-stained lymphocytes were defined as positively stained cells. The final IHC score was calculated using the average proportion of positively stained cells among lymphocyte cells in five random fields.

Statistical analysis. Statistical analysis was performed using SPSS version 17.0 statistical software (SPSS Inc.). The results are expressed as mean ± standard deviation (SD). One-way analysis of variance followed by the Student-Neumann-Keuls post hoc test was used for comparison among the GC, GU and HD groups. The Student's t-test was used for comparing the NK cell ratio between cancer associated death and those who were still alive after 5 years. The correlation of NK cell levels between serum and paired tumor tissue samples was analyzed by Spearman correlation analysis. The sensitivity and specificity to identify GC and HD based on the peripheral NK cell level were analyzed and the best cutoff was determined by receiver-operating characteristic (ROC) curve analysis. The $\chi^{2}$ test was used to determine the association between the level of peripheral NK cells and clinicopathological features. Clinical and pathological data at the time of resection were analyzed to identify factors that influenced the prognosis via the Cox proportional hazards model. Multivariate analysis was performed by the Cox proportional hazards regression model. Kaplan-Meier analysis with a log-rank test was performed to determine the overall survival (OS) of patients with GC based on the level of peripheral NK cells. P<0.05 was considered to indicate statistical significance.

Results

Distribution of lymphocyte subsets in patients with gastric diseases. Flow cytometry was used to detect the distribution of peripheral blood lymphocyte subsets in 80 HDs (age, 59.77±12.06 years; 50 male, 30 female), 80 cases of GU (age, 60.26±11.23 years; 42 male, 38 female) and 122 cases of GC (age, 56.41±11.92 years; 37 male, 85 female) (Fig. 1). CD3+, CD4+ and CD8+ T cells, as well as CD19+ B cells, were lower in patients with GC than in HDs but with no
statistical significance (P>0.05; Fig. 1A-D). Tregs levels were higher in patients with GC than in HDs or cases of GU, but there was no significant difference (P>0.05; Fig. 1E). Of note, the level of NK cells in patients with GC was significantly higher than that in HDs (P<0.001; 95% CI=7.51-12.51) and patients with GU (P<0.001; 95% CI=8.31-13.67; Fig. 1E).

**NK cell levels are correlated between paired serum and tumor samples from patients with GC.** Next, IHC analysis of NK cells (CD56) was performed in samples from patients with GC (n=20) and ulcer tissue samples from patients with GU (n=3), revealing that the NK cell level in GC tissues was notably higher compared with in GU tissues (Fig. 2A). Further comparison revealed a strong positive correlation between the NK cell levels of paired tumor serum and tissue samples from patients with GC (Spearman R=0.898; P<0.001, Fig. 2B).

**Peripheral NK cell levels in patients with GC are associated with clinicopathological features.** To determine the clinical importance of peripheral NK cell levels in patients with GC, the association of the peripheral levels of NK cells with various clinicopathological features in 122 patients with GC was determined. High NK cell levels were defined as >15.16% and low NK cell levels as ≤15.16% based on the previously determined NK cell level cutoff in patients with GC. χ² test indicated that high levels of peripheral NK cells were associated with the N stage, T stage and TNM stage (Table I). However, multivariate analysis suggested that high levels of peripheral NK cells were only independently associated with the T stage [P=0.031; hazard ratio (HR)=3.278; 95% CI: 1.113-9.656].

**High levels of NK cells in patients with GC are linked to poor survival.** Kaplan-Meier survival curves were drawn to determine the association of the levels of peripheral NK cells with OS. The results indicated that patients with high peripheral NK cell levels had a shorter OS than those with low levels of NK cells (P=0.004; Fig. 4A). In addition, at the 5-year follow-up, 69 patients had died, while 53 patients remained alive, with a 5-year mortality rate of 56.6%. The median proportion of NK cells was significantly higher in patients who had deceased (20.77%; IQR, 16.38-34.38%) than in those who were still alive after 5 years (17.50%; IQR, 12.80-20.82%; P=0.002; Fig. 4B). Next, multivariate analysis suggested that the level of peripheral NK cells were independent predictors of OS in patients with GC (P=0.018; HR=2.637; 95% CI: 1.305-5.328; Table II).
Discussion

The present study aimed to investigate the diagnostic and prognostic value of peripheral lymphocyte subsets in GC. The levels of peripheral CD3⁺, CD4⁺ and CD8⁺ T cells, CD19⁺ B cells and Tregs in patients with GC were not significantly different from those in HDs, but the proportion of peripheral NK cells in patients with GC (18.77%) was significantly higher than that in HDs (10.85%, P<0.001) and cases of GU (11.89%, P<0.001). ROC curve analysis suggested that the peripheral NK cell levels may be used as a diagnostic marker for patients with GC. In addition to CEA, CA19-9 and CA72-4 serum markers are widely used for the early diagnosis of GC (25-27). Recent studies have indicated that non-coding RNAs, including Homo sapiens circular RNA 0000467, as well as epigenetic changes such as RAS association domain family member 10 (RASSF10) hypermethylation, Helicobacter pylori infection, T stage and other molecular markers (28), may also act as diagnostic markers for GC (30,36,37). In the present study, the peripheral NK cell levels were determined to be an independent prognostic factor in patients with GC and patients who died within 5 years had a higher level of peripheral NK cells. Furthermore, the detection of NK cells only requires peripheral blood extraction, which is convenient to test and associated with low cost for patients. In the present study, the specificity and sensitivity of the NK cell ratio were slightly better than those for established prognostic markers for GC, including CEA and CA19-9. The present study determined that the NK cell ratio in the serum exhibited a positive correlation with that in matched GC tumor tissue samples. In the future, the NK cell ratio may be implemented in routine diagnostic/prognostic procedures for GC. However, the present study was limited by the sample size of patients with GC and HDs. In addition, only common peripheral blood lymphocytes were examined and the role of the proportion of NK cells in the prognosis and diagnosis of GC patients was demonstrated. However, there may be other lymphocyte clusters that warrant exploration.

In conclusion, the present study indicated that the peripheral NK cell levels may be used to identify patients with GC and are associated with certain clinicopathological
factors of malignancy. Of note, high levels of peripheral NK cells were associated with poor prognosis. The present study demonstrated that the peripheral NK cell levels may be a good diagnostic and prognostic marker for patients with GC.

Acknowledgements

The authors thank Dr Nicole Okoh (Liwen Bianji, Edanz Editing China; www.liwenbianji.cn/ac) for editing the English text of a draft of this manuscript.

Table I. Association between the characteristics of patients with gastric cancer and NK cell ratios in peripheral blood.

| Clinicopathological feature | NK cell level | Total (n) (%) | \( \chi^2 \)-value | P-value |
|-----------------------------|---------------|---------------|---------------------|---------|
| Sex                         |               |               |                     |         |
| Male                        | Low (n=30) (%)| High (n=92) (%)|                     |         |
| Female                      |               |               |                     |         |
| Age (years)                 |               |               |                     |         |
| \( \leq 60 \)               |               |               |                     |         |
| >60                         |               |               |                     |         |
| Tumor diameter (cm)         |               |               |                     |         |
| \( \leq 4 \)                |               |               |                     |         |
| >4                          |               |               |                     |         |
| Tumor location              |               |               |                     |         |
| Upper                       |               |               |                     |         |
| Middle                      |               |               |                     |         |
| Lower                       |               |               |                     |         |
| Tumor differentiation       |               |               |                     |         |
| High                        |               |               |                     |         |
| Low                         |               |               |                     |         |
| CA19-9 (U/ml)               |               |               |                     |         |
| \( \leq 37 \)               |               |               |                     |         |
| >37                         |               |               |                     |         |
| CEA level (ng/ml)           |               |               |                     |         |
| \( \leq 5 \)                |               |               |                     |         |
| >5                          |               |               |                     |         |
| HP infection                |               |               |                     |         |
| -                           |               |               |                     |         |
| +                           |               |               |                     |         |
| TNM stage                   |               |               |                     |         |
| I                           |               |               |                     |         |
| II                          |               |               |                     |         |
| III                         |               |               |                     |         |
| T stage                     |               |               |                     |         |
| 1                           |               |               |                     |         |
| 2                           |               |               |                     |         |
| 3                           |               |               |                     |         |
| 4                           |               |               |                     |         |
| N stage                     |               |               |                     |         |
| 0                           |               |               |                     |         |
| 1                           |               |               |                     |         |
| 2                           |               |               |                     |         |
| 3                           |               |               |                     |         |

NK, natural killer; HP, Helicobacter pylori.
Table II. Univariate and multivariate analyses of prognostic factors for overall survival in patients with gastric cancer.

| Variable                                                                 | Univariate analysis | Multivariate analysis |
|--------------------------------------------------------------------------|---------------------|-----------------------|
|                                                                         | P-value  | HR  | 95% CI  | P-value |
| Sex [male (n=85) vs. female (n=37)]                                       | 0.328    | 1.303 | 0.767-2.214 | NS     |
| Age [years; ≤60 (n=82) vs. >60 (n=40)]                                    | 0.574    | 0.864 | 0.519-1.438 | NS     |
| Tumor diameter [cm; ≤4 (n=45) vs. >4 (n=77)]                            | 0.155    | 0.702 | 0.431-1.144 | NS     |
| Tumor location [upper/middle (n=39) vs. lower (n=73)]                    | 0.597    | 1.136 | 0.708-1.823 | NS     |
| Tumor differentiation [high (n=79) vs. low (n=43)]                       | 0.209    | 0.828 | 0.616-1.112 | NS     |
| CA19-9 level [U/ml; ≤37 (n=95) vs. >37 (n=27)]                           | 0.362    | 1.316 | 0.729-2.375 | NS     |
| CEA level [ng/ml; ≤5 (n=73) vs. >5 (n=49)]                               | 0.483    | 1.199 | 0.722-1.993 | NS     |
| HP infection [- (n=74) vs. + (n=48)]                                     | 0.096    | 1.505 | 0.930-2.435 | NS     |
| T stage [I, II (n=75) vs. III, IV (n=47)]                                | 0.037    | 1.671 | 1.033-2.704 | NS     |
| N stage [0, 1 (n=74) vs. 2, 3 (n=48)]                                    | 0.015    | 1.820 | 1.124-2.949 | 0.064  |
| NK cells [high (n=92) vs. low (n=30)]                                    | 0.007    | 2.637 | 1.305-5.328 | 0.018  |

NK, natural killer; HP, Helicobacter pylori; NS, not significant.

Figure 4. Association between peripheral NK cell levels and survival of patients with gastric cancer. (A) Kaplan-Meier plot depicting the association between peripheral NK cell levels (low or high) and overall survival (P=0.004; 95% CI=1.27-3.71). (B) Boxplot illustrating peripheral NK cell levels according to patients' survival status after 5 years (P=0.019; 95% CI=1.158-4.804). The NK levels of all patients in these groups were tested before surgery. NK, natural killer.

Funding
This study was supported by the National Natural Science Foundation of China (grant no. 81672409), Jiangsu Provincial Medical Youth Talent (grant no. QNR2016700), ‘333 Talent’ Cultivating Project of Jiangsu Province (grant no. BRA2018394), Postgraduate Research & Practice Innovation Program of Jiangsu Province (grant no. SJCX20_1153; SJCX20_1159; KYCX20_2674) and the Scientific and Technological Innovation and Demonstration Project of Nantong City (grant no. MS12018061).

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Authors’ contributions
WJX and YLH conceived and designed the experiments. YYC and YF performed the experiments. QSM, JZL, XC and PM analyzed the data. YYC and YFL wrote the manuscript. WL and YFL searched the literature and performed statistical analysis. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The present study was approved by the Ethics Committee of Nantong University (Nantong, China). Written informed consent was obtained from each participant.

Patient consent for publication
Not applicable.
Competing interests

The authors declare that they have no competing interests.

References

1. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 64: 252-271, 2014.
2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns of ELOGBAC-Cancer Global Cancer Observatory. CA Cancer J Clin 68: 3-26, 2018.
3. Wang B, Xu D, Yu X, Ding T, Rao H, Zhan Y, Zheng L and Li L: Association of intra-tumoral infiltrating macrophages and regulatory T cells is an independent prognostic factor in gastric cancer after radical resection. Ann Surg Oncol 18: 2585-2593, 2011.
4. Chow MT, Möller A and Smyth MJ: Inflammation and immune surveillance in cancer. Semin Cancer Biol 22: 23-32, 2012.
5. Zarin P, Wang GW, Mohtashami M, Wiest DL and Zúñiga-Pflücker JC: Enforcement of γδ lineage commitment by the pre-T-cell receptor in precursors with weak γδ TCR signals. Proc Natl Acad Sci USA 111: 5658-5663, 2014.
6. Park K, Huang Z, Xu L, Xu D and Kappes DJ: TCR-mediated ThpOK induction promotes development of mature (CD24+) gammadelta thymocytes. EMBO J 29: 2329-2341, 2010.
7. Bauer S, Groh V, Wu J, Steinkel A, Phillips JH, Lanier LL and Spies T: Th17 fate: Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 1999. 285: 727-729. J Immunol 200: 2231-2233, 2018.
8. Sardinha LR, Elias RM, Mosca T, Bastos KR, Marinho CR, D’Império Lima MR and Alvarez JM: Contribution of NK, NK T, gamma delta T, and alpha beta T cells to the gamma interferon response required for liver protection against trypanosoma cruzi. Infect Immun 74: 2031-2042, 2006.
9. Xu YF, Lu Y, Cheng H, Shi S, Xu J, Long J, Liu L, Liu C and Xu Y: Abnormal distribution of peripheral lymphocyte subsets induced by PDAC modulates overall survival. Pancreatology 14: 295-301, 2014.
10. Yu A, Mansure JJ, Solanki S, Chaturvedi AK, Chandrasekharan V, Nam S, Gellert M, Xavier R, He Y and Hsu WC: FoxP3(+) regulatory T cells in tumor‑infiltrating lymphocytes, tumor‑draining lymph nodes and peripheral blood lymphocytes in patients with gastric cancer. Cancer Sci 101: 1947-1954, 2010.
11. Isebo Y, Nashimoto A, Akazawa K, Oda I, Hayashi K, Miyashiro I, Katai H, Tsujitani S, Kodera Y, Seto Y and Kaminski M: Gastric cancer treatment in Japan: 2008 Annual report of the JGCA nationwide registry. Gastric Cancer 14: 301-316, 2011.
12. Ning S, Wei W, Li J, Hou B, Zhong J, Xie Y, Liu H, Mo X, Chen J and Zhang L: Clinical significance and diagnostic capacity of serum Tki, CEA, CA 125, and CA 72-4 in lung adenocarcinoma patients with non-small cell lung cancer. J Cancer 9: 77-83, 2018.
13. Feng F, Tian Y, Xu G, Liu Z, Liu S, Zheng G, Guo M, Lian X, Fan D and Zhang H: Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer. BMC Cancer 17: 737, 2017.
14. Shi M, Wang H, Wei K, Zhang J and You C: Five common tumor biomarkers and CEA for diagnosing early gastric cancer: A protocol for a network meta-analysis of diagnostic test accuracy. Medicine (Baltimore) 97: e5077, 2018.
15. Yoon JH, Park YG, Nam SW and Park WS: The diagnostic value of serum gastrokine 1 (GKN1) protein in gastric cancer. Cancer Sci 8: 5507-5514, 2019.
16. Lu J, Zhang PY, Xie JW, Wang JB, Lin JX, Chen QY, Cao LL, Huang CM, Li P and Zheng CH: Hsa_circ_0004676 promotes cancer progression and serves as a diagnostic and prognostic biomarker for gastric cancer. J Clin Lab Anal 33: e22726, 2019.
17. Xue WJ, Feng Y, Wang F, Li P, Liu YF, Guo YB, Wang ZW and Mao QS: The value of serum RASSF10 hypermethylation as a diagnostic and prognostic tool for gastric cancer. Tumour Biol 37: 11249-11257, 2016.
18. Abbaszadegan MR, Tagheichian N, Abarabi A and Moghbeli M: Mael: Cancer-testis antigen as a diagnostic marker in primary stages of gastric cancer with Helicobacter pylori infection. J Gastrointest Cancer 51: 17-22, 2020.
19. Kouzu K, Tsujimoto H, Hiraki S, Nomura S, Yamamoto J and Ueno H: Diagnostic accuracy of T stage of gastric cancer from the view point of application of laparoscopic proximal gastrectomy. Mol Clin Oncol 8: 773-778, 2018.
20. Deng J, Liu J, Wang W, Sun Z, Wang Z, Zhou Z, Xu H and Liang H: Validation of clinical significance of examined lymph node count for accurate prognostic evaluation of gastric cancer for the eighth edition of the American joint committee on cancer (AJCC) TNM staging system. Chin J Cancer Res 30: 477-491, 2018.
21. Wei J, Yao T, Wang Y, Li L, Pan C and Zhang N: Prognostic analysis of stage III gastric cancer after curative surgery according to the newest TNM classification. Clin Transl Oncol 21: 232-238, 2019.
22. Xu TP, Wang WY, Ma F, Shuai Y, Zhao K, Wang YF, Li W, Xia R, Chen WM, Zhang LB and Zhang J: Identification of long noncoding RNA FOXD2-AS1 promotes carcinogenesis by epigenetically silencing Ephp3 through EZH2 and LSD1, and predicts poor prognosis in gastric cancer. Oncogene 37: 5020-5036, 2018.
23. Moghbeli M, Makhdoomi Y, Soltanii Delgosha M, Abarabi A, Dakhkhah E, Memar B, Abdollahi A and Abbaszadegan MR: ErbB1 and ErbB3 co-over expression as a prognostic factor in gastric cancer. Biomark 24: 249-255, 2019.